January 1, 1985Clinical and Experimental Hypertension
Slow-Release Nifedipine as a Single or Additional Agent in the Treatment of Essential Hypertension—A Placebo-Controlled Crossover Study
Why the study?
Does slow-release nifedipine reduce blood pressure in subjects with essential hypertension?
Population
19 subjects with essential hypertension, 14 of whom continued previous antihypertensive medication.
Comparison
Slow-release nifedipine 20 mg twice daily for 6… vs Placebo tablets twice daily for 6 weeks
Design
RCT, random order, double-blind
Follow-up
6 weeks per treatment phase
Authors
Discussion
Loading...
Member takes
Implication
Supports nifedipine for BP control in essential hypertension; confirms efficacy as monotherapy or add-on.
Structured PICO
Does slow-release nifedipine reduce blood pressure in subjects with essential hypertension?
P
Population
19 subjects with essential hypertension (14 male, 5 female, ages 34-72 years), 14 of whom continued previous antihypertensive medication.
I
Intervention
Slow-release nifedipine 20 mg twice daily for 6 weeks
C
Comparator
Placebo tablets twice daily for 6 weeks
O
Outcome
Supine and standing mean blood pressuresurrogate
Slow-release nifedipine 20 mg twice daily is an effective hypotensive agent, either as monotherapy or added to existing antihypertensive therapy.
Cite This Study
Wing et al. (1985) studied this question.